Tulin Budak-Alpdogan
Overview
Explore the profile of Tulin Budak-Alpdogan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Odat O, Elbezanti W, Gowda K, Srivastava S, Amin S, Jonnalagadda S, et al.
Front Pharmacol
. 2024 Oct;
15:1436786.
PMID: 39411073
Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients...
2.
Garcia A, Qureshi M, Dhawan I, Rafferty W, Budak-Alpdogan T, Giordano S
ACG Case Rep J
. 2024 Sep;
11(9):e01462.
PMID: 39280888
[This corrects the article DOI: 10.14309/crj.0000000000001277.].
3.
Raddell T, Ashraf F, Zhao X, Abramian O, Budak-Alpdogan T
Acta Haematol
. 2024 Jul;
:1-6.
PMID: 39074451
Introduction: Nodular pulmonary amyloidosis (NPA) is a localized form of light chain (AL) amyloidosis often found incidentally and typically has an indolent and benign disease course treated with resection or...
4.
Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T, et al.
Heliyon
. 2024 Jul;
10(12):e33091.
PMID: 39021902
Multiple Myeloma (MM) is a malignant expansion of plasma cells in the bone marrow (BM), resulting in a disease characterized by symptoms of end organ damage from light chain secretion,...
5.
Al-Odat O, Nelson E, Budak-Alpdogan T, Jonnalagadda S, Desai D, Pandey M
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001443
MM is a common type of cancer that unfortunately leads to a significant number of deaths each year. The majority of the reported MM cases are detected in the advanced...
6.
Garcia A, Qureshi M, Dhawa I, Rafferty W, Budak-Alpdogan T, Giordano S
ACG Case Rep J
. 2024 Feb;
11(2):e01277.
PMID: 38328767
Amyloidosis is a group of rare deposition diseases marked by the accumulation of abnormal fibrillar proteins in the extracellular space of various tissues. In both AL and AA amyloidosis, the...
7.
Garcia A, Qureshi M, Dhawan I, Allen A, Budak-Alpdogan T, Giordano S
ACG Case Rep J
. 2023 Dec;
10(12):e01215.
PMID: 38107609
Follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma. Although extranodal involvement of the gastrointestinal (GI) tract is common in lymphomas, primary GI-FL confined to the GI tract is...
8.
Elbezanti W, Challagundla K, Jonnalagadda S, Budak-Alpdogan T, Pandey M
Pharmaceuticals (Basel)
. 2023 Mar;
16(3).
PMID: 36986514
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have...
9.
Al-Odat O, Guirguis D, Schmalbach N, Yao G, Budak-Alpdogan T, Jonnalagadda S, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36614089
Over the past two decades, the natural history of multiple myeloma (MM) has evolved dramatically, owing primarily to novel agents targeting MM in the bone marrow microenvironment (BMM) pathways. However,...
10.
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson N, et al.
Blood
. 2022 Nov;
141(6):567-578.
PMID: 36399715
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous...